Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 285

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 285
---
 hyperventilation/breathing problems (AUC=0.75), and epilepsy (AUC=0.89). The data supports the development of assays based on the analysis of cell-free brain/other organ-enriched miRNAs detectable in blood plasma to facilitate better understanding of RTT-associated pathophysiological processes and development of therapeutics for RTT. (PLoS One, 2019; doi: 10.1371/journal.pone.0218623; Rett Syndrome Foundation Research Trust Conference, 2023, Boston MA, poster presentation) 173 On June 19, 2024, DiamiR made an oral presentation at the 2024 Rett Syndrome Scientific Meeting titled “Circulating Organ-enriched microRNAs as Biomarkers of Rett Syndrome” ( https://www.prnewswire.com/news-releases/DiamiR-announces-oral-presentation-on-recent-advances-of-its-microrna-biomarker-platform-at-2024-international-rett-syndrome-foundation-scientific-meeting-302170263.html?tc= eml_cleartime). On behalf of DiamiR, Dr. Sheinerman presented findings from a Rett microRNA biomarker study conducted between 2021 and 2024. Levels of 44 microRNAs were analyzed in plasma samples of 163 study participants, including 81 Rett syndrome patients and 82 age-matched individuals without Rett syndrome, of three age groups: younger than 5 years old, 5 to 15 years old, and older than 16 years old. The blood samples for the study were provided by the Tri-State Rett Syndrome Center, Montefiore Medical Center. In line with DiamiR’s previously described results (see Business section, Circulating Organ-enriched miRNAs as Biomarkers of Rett Syndrome), the microRNA panel effectively differentiated study participants with Rett syndrome. To develop a marketable RTT diagnostic solution, DiamiR plans to offer both sequencing services (of the MECP2gene) and its proprietary miRNA panel. DiamiR is currently evaluating 3 rdparty vendors to develop a custom NGS assay for Rett syndrome on a MiSeQ platform (Illumina). BEYOND BRAIN HEALTH: UNIVERSAL SCREENING TEST DiamiR believes its core miRNA technology is robust and applicable to early detection of disease pathology in different organs, not only in the brain